Kelun-Biotech

Kelun-Biotech, a holding subsidiary of Sichuan Kelun Pharmaceutical, is a clinical-stage biotech company engaged in biologic therapeutics as well as small molecule discovery and development.

Blue race track
Favicon Fierce Pharma

Merck grows more ambitious about 'workhorse' TROP2 ADC

Merck has already registered 15 global phase 3 trials for its Kelun-partnered TROP2 antibody-drug conjugate, sac-TMT.
Angus Liu Oct 20, 2025 4:00pm
windmill turbines in the Netherlands

Windward generates $200M with Novo Holdings, OrbiMed in tow

Jan 10, 2025 10:02am
change direction new plan alter arrows move reprioritize

Merck bags one Kelun ADC for $37.5M, boots out another asset

Aug 20, 2024 6:43am
Merck

Merck trims mushrooming ADC pipeline by axing 2 Kelun programs

Oct 23, 2023 9:00am
cash

Synaffix, MacroGenics crack open ADC pact, tack on $2.2B to deal

Mar 14, 2023 10:30am
war chest treasure chest gold money cash box

Merck signs eye-popping $9.3B biobucks deal with Kelun-Biotech

Dec 22, 2022 9:00am